Semaphorin 5A promotes gastric cancer invasion/metastasis via urokinase-type plasminogen activator/phosphoinositide 3-kinase/protein kinase B

Digestive Diseases and Sciences

Volumn 58, Issue 8, 2013, Pages 2197-2204

  Pan, Guoqing ^a   Zhu, Zhu ^a   Huang, Jian ^a   Yang, Chenggang ^a   Yang, Ying ^a   Wang, Yingxia ^a   Tuo, Xiaoyu ^a   Su, Guomiao ^a   Zhang, Xiangling ^a   Yang, Zhi ^a   Liu, Tao ^b  

^a KUNMING MEDICAL UNIVERSITY   (China)

^b Department of Gynecology   (China)

Author keywords

Gastric cancer; Phosphoinositide 3 kinase (PI3K); Protein kinase B (Akt); Semaphorin 5A; Urokinase type plasminogen activator (uPA)

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SEMAPHORIN; SEMAPHORIN 5A; UNCLASSIFIED DRUG; UROKINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MEDIATOR; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STOMACH CANCER; TUMOR INVASION; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MEMBRANE PROTEINS; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASMS, EXPERIMENTAL; NERVE TISSUE PROTEINS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; STOMACH NEOPLASMS; UP-REGULATION; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 84881479462     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-013-2666-1     Document Type: Article

References (17)

1. Foukakis T, Lundell L, Gubanski M, et al. Advances in the treatment of patients with gastric adenocarcinoma. Acta Oncol. 2007;46:277-285.
2. Harder J, Opitz OG. Gastric cancer-risk factors and medical therapy. Schweiz Rundsch Med Prax. 2006;95:1021-1028.
3. Hundahl SA, Phillips JL, Menck HR. The National Cancer Data Base Report on poor survival of US gastric carcinoma patients treated with gastrectomy: Fifth Edition American Joint Committee on Cancer staging, proximal disease, and the "different disease" hypothesis. Cancer. 2000;88:921-932.
4. Yazdani U, Terman JR. The semaphorins. Genome Biol. 2006;7:211-224.
5. Kolodkin AL, Matthes DJ, Goodman CS. The semaphorin genes encode a family of transmembrane and secreted growth cone guidance molecules. Cell. 1993;75:1389-1399.
6. Kruger RP, Aurandt J, Guan KL. Semaphorins command cells to move. Nat Rev Mol Cell Biol. 2005;10:789-800.
7. Pan GQ, Ren HZ, Wen JF, et al. Expression of semaphorin 5A and its receptor plexin B3 contributes to invasion and metastasis of gastric carcinoma. World J Gastroenterol. 2009;15:2800-2804.
8. Pan G, Lv H, Ren H, Wen J, et al. Elevated expression of semaphorin 5A in human gastric cancer and its implication in carcinogenesis. Life Sci. 2010;86:139-144.
9. Pan G, Zhang X, Ren J, Zhang S, Li J, et al. Semaphorin 5A, an axon guidance molecule, enhances the invasion and metastasis of human gastric cancer through activation of MMP9. Pathol Oncol Res. 2013;19:11-18.
10. Mehlen P, Puisieux A. Metastasis: a question of life or death. Nat Rev Cancer. 2006;6:449-458.
11. Veit C, Genze F, Menke A, et al. Activation of phosphoinositide 3-kinase and extracellular signal regulated kinase is required for glial cell line derived neutrophic factor-induced migration and invasion of pancreatic carcinoma cells. Cancer Res. 2004;64:5291-5300.
12. Qian Y, Zhong X, Flynn DC, et al. ILK mediates filament rearrangements and cell migration and invasion through PI3K/Akt/Rac1 signaling. Oncogene. 2005;24:3154-3165.
13. Legrand C, Polette M, Tournier JM, de Bentzmann S, et al. uPA/plasmin system-mediated MMP-9 activation is implicated in bronchial epithelial cell migration. Exp Cell Res. 2001;264:326-336.
14. Kunigal S, Gondi CS, Gujrati M, et al. SPARC-induced migration of glioblastoma cell lines via uPA/uPAR signaling and activation of small GTPase RhoA. Int J Oncol. 2006;29:1349-1357.
15. Look MP, van Putten WL, Duffy MJ, et al. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst. 2002;94:116-128.
16. Hou Y, Okamoto C, Okada K, et al. c-Myc is essential for urokinase plasminogen activator expression on hypoxia-induced vascular smooth muscle cells. Cardiovasc Res. 2007;75:186-194.
17. Xing RH, Rabbani SA. Regulation of urokinase production by androgens in human prostate cancer cells: effect on tumor growth and metastases in vivo. Endocrinology. 1999;140:4056-4064.